Genetic variations in the IFNAR1 gene significantly affect the efficacy of interferon-alpha (IFN-α) and interferon-beta (IFN-β) treatments used for conditions like hepatitis C and multiple sclerosis. Specific polymorphisms in IFNAR1 influence individual responses, leading to varying therapeutic outcomes, highlighting the importance of considering these genetic differences in personalized medical approaches.